Compare JPMorgan Chase & Co (JPM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Zoetis Inc — how do they compare? JPMorgan Chase & Co trades at $339.1 (market cap $900.78B), while Zoetis Inc trades at $76.1 (market cap $31.95B). The key difference: JPMorgan Chase & Co is far larger — about 28.2× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| JPM | ZTS | |
|---|---|---|
Market Cap | $900.78B | $31.95B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $346.91 | $156.76 |
52-Week Low | $282.84 | $71.91 |
Dividend Yield | 1.77% | 2.78% |
Enterprise Value | — | $39.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase trades at $341.10, down 0.6% on the day, with a bullish technical signal from moving averages and support at $339. The company reported strong Q1 and Q2 2026 earnings beats, with revenue growth from $169.4B in 2024 to $181.8B in 2025. Analyst consensus is Moderate Buy with a $374 price target, representing 9.6% upside potential. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings on April 14.
JPMorgan demonstrates solid fundamentals with consistent revenue growth and strong net income margins above 30%. The stock appears reasonably valued with a P/E of 14.6. Key risks include geopolitical tensions impacting banking operations and cybersecurity vulnerabilities from advanced AI systems. The bullish analyst sentiment and technical setup suggest potential for continued upside if earnings momentum persists.
Zoetis (ZTS) trades at $76.05, down 0.67% on the day, with a neutral technical signal and bearish moving averages. The company maintains strong fundamentals with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple securities class action lawsuits filed against the company, creating near-term uncertainty despite the launch of new product Lenivia in Canada and EU markets.
The stock presents a mixed outlook with attractive valuation metrics (P/E 12.55) and analyst consensus price target of $101.43 suggesting 33% upside potential. However, legal challenges and the recent earnings miss pose significant near-term risks. Institutional sentiment remains divided with 47% buy ratings versus 53% hold ratings, indicating cautious optimism amid legal headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
